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Abstract
Objectives: Surveys in various countries suggest 17% to 80% of doctors prescribe ‘placebos’ in routine practice, but
prevalence of placebo use in UK primary care is unknown.
Methods: We administered a web-based questionnaire to a representative sample of UK general practitioners. Following
surveys conducted in other countries we divided placebos into ‘pure’ and ‘impure’. ‘Impure’ placebos are interventions with
clear efficacy for certain conditions but are prescribed for ailments where their efficacy is unknown, such as antibiotics for
suspected viral infections. ‘Pure’ placebos are interventions such as sugar pills or saline injections without direct
pharmacologically active ingredients for the condition being treated. We initiated the survey in April 2012. Two reminders
were sent and electronic data collection closed after 4 weeks.
Results: We surveyed 1715 general practitioners and 783 (46%) completed our questionnaire. Our respondents were similar
to those of all registered UK doctors suggesting our results are generalizable. 12% (95% CI 10 to 15) of respondents used
pure placebos while 97% (95% CI 96 to 98) used impure placebos at least once in their career. 1% of respondents used pure
placebos, and 77% (95% CI 74 to 79) used impure placebos at least once per week. Most (66% for pure, 84% for impure)
respondents stated placebos were ethical in some circumstances.
Conclusion and implications: Placebo use is common in primary care but questions remain about their benefits, harms,
costs, and whether they can be delivered ethically. Further research is required to investigate ethically acceptable and cost-
effective placebo interventions.
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Introduction
Surveys in various countries suggest 17% to 80% of doctors
have prescribed ‘placebos’ in routine clinical practice,
[1,2,3,4,5,6,7,8,9,10,11,12] yet placebo use outside the context
of a clinical trial with full informed consent is generally considered
unethical. [13,14,15,16] The only survey of placebo use in the UK
was a 1976 qualitative study restricted to Welsh practitioners. [2]
Hence current prevalence of placebo use in UK primary care is
unknown.
A barrier to investigating placebo use is that confusion
surrounds the ‘placebo’ concept. [17,18,19,20,21,22] For example,
placebos are often characterized as inactive and nonspecific when
in fact they can be active, and have specific effects, especially for
relieving pain. [23,24,25,26,27] Since this was an empirical rather
than conceptual study we adopted a pragmatic approach and
asked doctors whether they used various treatments described as
placebos in other similar surveys. Our approach has the advantage
of being useful: patients, doctors, and policy makers care more
about whether particular treatments are effective and ethical than
whether these treatments carry the label ‘placebo’.
We aimed to discover if UK general practitioners (GPs)
prescribe placebos as frequently as elsewhere and also to
understand the conditions under which general practitioners find
placebos ethical. [13,14] Ethical placebos may have a role in
health care, for example in treating patients with chronic
osteoarthritic pain, where current best practice often involves
medications such as non-steroidal anti-inflammatory drugs
(NSAIDs) that have known harmful side effects. [28,29,30]Our
aim was not to study placebo use within the context of controlled
trials.
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Methods
Participants
Participants in this cross-sectional survey were randomly
sampled from among the UK general practitioners registered
with a clinician marketing service (Doctors.net); 71% of UK GPs
are registered with the service. Ethical approval was obtained from
the University of Oxford, and the survey was sent via email on 26
April 2012. Email reminders were sent out on 30 April and 4 May,
and the survey closed on 21 May 2012.
We required 655 responses for our sample to reflect the
population with 99% confidence (65%). Based on recent surveys,
[4,11] we predicted a response rate of between 40 to 60% and
emailed the survey to 1,715 general practitioners.
Defining pure and impure placebos
Following other recent surveys we adopted the convention of
dividing placebos into ‘pure’ and ‘impure’. [4,7,10,11,12] Pure
placebos are interventions such as sugar pills (which are available
commercially [31]) or saline injections without direct pharmaco-
logically active ingredients for the condition being treated. Impure
placebos are substances, interventions or ‘therapeutic’ methods
which have known pharmacological, clinical or physical value for
some ailments but lack specific therapeutic effects or value for the
condition for which they have been prescribed. These may
include:
N Positive suggestions
N Nutritional supplements for conditions unlikely to benefit from
this therapy (such as vitamin C for cancer)
N Probiotics for diarrhea
N Peppermint pills for pharyngitis
N Antibiotics for suspected viral infections [5]
N Sub-clinical doses of otherwise effective therapies [32]
N Off-label uses of potentially effective therapies
N Complementary and Alternative medicine (CAM) whose
effectiveness is not evidence-based [33,34]
N Conventional medicine whose effectiveness is not evidence-
based [35,36,37,38]
N Diagnostic practices based on the patient’s request or to calm
the patient such as
N Non-essential physical examinations
N Non-essential technical examinations of the patient (blood
tests, X-rays)
Survey instrument
To compare our results with other surveys of placebo use we
adapted recently published questionnaires for a UK audience.
[4,7,9,10,11,12] We piloted our questionnaire with GP colleagues
at Oxford and Southampton (n=21) to ensure face validity. The
questionnaire asked respondents to note how frequently (if at all)
they used placebo interventions. Additional items asked about
reasons for placebo use, circumstances under which practitioners
felt placebo use was ethically acceptable, and what practitioners
told patients when they prescribed placebo interventions. To
address the risk of social desirability bias in our responses our
questionnaire began with two case studies that avoided using the
term ‘placebo’, one about using antibiotics for throat infections
and the other about a hospital patient who responded when the
intravenous painkillers were replaced by saline injection. To
minimize conceptual ambiguity we included our definitions of
pure and impure placebos on the first and subsequent pages of the
questionnaire, and respondents were offered the option to answer
that a given intervention was not a placebo. Our questionnaire
included open-ended questions where respondents could provide
comments about their definitions of placebos.
Statistical analysis
Participants entered their responses directly into an online
survey using Confirmit. [39] We used descriptive statistics (means
and 95% confidence intervals) to describe practitioner character-
istics and frequencies of placebo use. We reported how often
respondents used all pure and all impure placebos at least once in
their career (mean and 95% CI). For each type of placebo we
categorized prevalence of use into: frequent (daily or approxi-
mately once per week), occasional (approximately once per month
or once per year) and rare/never (more than once per year or
never). We also noted reasons for prescribing placebos (mean and
95% CI), and attitudes towards the ethics of placebos. We
analyzed differences (RR and 95% CI) between usage among
respondents who stated placebos were categorically unacceptable
in routine practice and those who stated placebos were sometimes
acceptable.
We used Fisher’s exact test to investigate whether placebo use
was associated with gender, year of qualification (stratifying 1989
or earlier/1990–1999/2000 or later), number of patients treated
per week (100 or less/101 to 150/151 or more), number of days
per week in current practice (0–3/3.5–4.5/5 or more). A
Bonferroni correction was used to allow for the 14 types of
placebo against which each characteristic (gender, year qualified,
etc.) was tested: each test was deemed significant if p,0.0036,
giving a 5% type I error rate across all 14 tests for each
characteristic. All analyses were conducted using STATA (version
11).
Results
Respondent characteristics
Of the 1715 primary care practitioners sent the questionnaire
783 (46%) responded. There were more male (55%) respondents,
the average year of qualification was 1993 (range 1964 to 2007,
mode= 2000), the average days per week in current practice were
4 (range 0.5 to 6), and the mean number of patients treated per
week was 123 (range 6 to 450). Our participants were similar to
those registered with the General Medical Council (GMC): 52% of
UK general practitioners are male, and the mode of UK GP
qualification year is 2000. [40,41,42] One respondent reported
treating zero patients per week and working clinically zero days
per week and we excluded them from the analysis.
Pure placebos: prevalence of use
12% (95% CI 10 to 15) of respondents reported using pure
placebos (sugar pills or saline injections) at least once in their
career (see Table 1). 1% (95% CI 0 to 2) of respondents reported
using pure placebos at least once per week (see Table 2).
Reasons for prescribing pure placebos varied. 55% (95% CI 51
to 59) of respondents reported prescribing pure placebos to induce
possible psychological treatment effects, 33% (95% CI 30 to 36) to
calm patients, 32% (95% CI 29 to 35) because the patient
requested a therapy, and 31% (95% CI 28 to 34) to treat non-
specific complaints.
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Impure placebos: prevalence of use
97% (95% CI 96% to 98) of respondents reported using impure
placebos at least once in their career (see Table 1), and 77% (95%
CI 74 to 79) reported using impure placebos frequently (at least
once per week, see Table 2). Several impure placebos were used
frequently by at least a quarter of GPs. These included non-
essential physical examinations (54%, 95% CI 50 to 57), positive
suggestions (52%, 95% CI 48 to 55), non-essential technical
examinations (31%, 95% CI 28 to 34), conventional medicine
whose effectiveness is not evidence-based (26%, 95% CI 23 to 29),
and antibiotics for suspected viral infections (25%, 95% CI 22 to
28).
Common reasons for prescribing impure placebos were similar
to reasons for prescribing pure placebos. 50% (95% CI 47 to 54)
reported prescribing them for a possible psychological treatment
effect, 45% (95% CI 42 to 49) because the patient requested a
therapy, 35% (95% CI 32 to 39) for non-specific complaints, and
32% (95% CI 29 to 35) to calm patients.
Pure placebos: ethical attitudes
66% (95% CI 63 to 70) of respondents felt there were
circumstances in which pure placebos were ethically acceptable
(see Table 3). Yet 82% (95% CI 79 to 85) stated pure placebos
were unacceptable when they involved deception, and 90% (95%
CI 88 to 92) stated they were unethical when they endangered
patient/doctor trust. Half (53%) of doctors who prescribed pure
placebos told patients that ‘this therapy has helped many other
patients,’ a quarter (25%) told patients that the treatment
promoted self-healing and a tenth (9%) told the patient the
treatment was a placebo. Doctors who reported finding pure
placebos ‘never acceptable in clinical practice’ were less likely to
prescribe them (6% versus 15%, relative rate (RR) 0.41, 95% CI
0.25 to 0.69). Respondents who reported finding pure placebos
‘never acceptable’ prescribed them for possible psychological
treatment effect or to offer treatment to those with untreatable/
incurable disease. Sample sizes were too small to formally analyze
reasons for placebo use among doctors who found pure placebos
never ethically acceptable.
Table 1. Summary of placebo usage.
Frequency (percentage, 95% CI)
Has used at least once in career Has never used/is not a placebo
Pure placebos 12% (9.0 to 14.6) 88% (85.4 to 90.0)
Impure placebos 97% (96.0 to 98.6) 3% (1.7 to 4.0)
doi:10.1371/journal.pone.0058247.t001
Table 2. Frequency of placebo use by type of placebo.
Frequency (percentage, 95% CI) This is not a placebo
Frequently (daily or
approximately once per
week)
Occasionally (approximately
once per month or at least
once in the last year)
Rare (less than
once per year or
never)
PURE PLACEBOS 0.90% (0.2 to 1.6) 1.5% (0.7 to 2.4) 97.4% (96.3 to 98.5) 0.3% (0.0 to 0.6)
Sugar Pills 0.5% (0 to 1.0) 1.0% (0.3 to 1.7) 97.8% (96.8 to 98.8) 0.6% (0.1 to 1.2)
Saline injections 0.4% (0 to 0.8) 1.4% (0.6 to 2.2) 97.6% (96.5 to 98.6) 0.6% (0.1 to 1.2)
IMPURE PLACEBOS 77.0% (74.0 to 79.9) 18.0% (15.3 to 20.7) 4.6% (3.1 to 6.1) 0.4% (0.0 to 0.8)
Positive suggestions 51.7% (48.2 to 55.2) 19.6% (16.8 to 22.3) 18.3% (15.6 to 21.0) 10.5% (8.3 to 12.6)
Nutritional supplements 5.9% (4.2 to 7.5) 23.9% (20.9 to 26.9) 68.8% (65.6 to 72.0) 1.4% (0.6 to 2.2)
Probiotics for diarrhea 9.0% (7.0 to 11.0) 39.0% (35.6 to 42.4) 45.5% (42.0 to 49.0) 6.5% (4.8 to 8.3)
Peppermint pills for pharyngitis 1.8% (0.9 to 2.7) 6.5% (4.8 to 8.3) 89.8% (87.6 to 91.9) 1.9% (1.0 to 2.9)
Antibiotics for suspected viral infections 25.2% (22.2 to 28.2) 51.2% (47.6 to 54.7) 19.7% (16.9 to 22.5) 4.0% (2.6 to 5.3)
Sub-clinical doses of effective therapies 4.9% (3.6 to 6.4) 34.4% (31.1 to 37.7) 57.3% (53.8 to 60.8) 3.5% (2.2 to 4.7)
Off-label uses of a potentially effective therapy 13.0% (10.7 to 15.4) 45.4% (41.9 to 48.9) 33.6% (30.3 to 36.9) 7.9% (6.0 to 9.8)
Complementary and Alternative medicine (CAM)
whose effectiveness is not evidence-based
6.8% (5.0 to 8.5) 44.2% (40.8 to 47.7) 44.8% (41.3 to 48.2) 4.2% (2.8 to 5.6)
Conventional medicine whose effectiveness is not
evidence-based
26.2% (23.1 to 29.3) 51.2% (47.6 to 54.7) 16.0% (13.4 to 18.6) 6.6% (4.9 to 8.4)
Non-essential physical examinations 53.6% (50.1 to 57.1) 28.6% (25.5 to 31.8) 12.4% (10.1 to 14.7) 5.4% (3.8 to 7.0)
Non-essential technical examinations of the patient
(blood tests, X-rays)
31.2% (28.0 to 34.4) 50.5% (47.0 to 54.0) 13.6% (11.2 to 16.0) 4.7% (3.2 to 6.2)
OTHER* 36.4% (33.0 to 39.7) 27.3% (24.3 to 30.4) 18.2% (15.5 to 20.9) 18.2% (15.5 to 20.9)
*CBT, ferrous sulphate, gesture and intonation in addition to positive suggestion, medication, physiotherapy, joint injection, reassurance, referral to website,
reassurance, ‘tell them my own or my family member with the same problem’, unnecessary referrals.
doi:10.1371/journal.pone.0058247.t002
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Impure placebos: ethical attitudes
84% (95% CI 82 to 87) of respondents agreed there were some
circumstances in which impure placebos were ethically accepable
(see Table 3). Yet 82% (95% CI 80 to 85) stated impure placebos
were unacceptable when they involved deception and 94% (95%
CI 92 to 95) stated they were unethical when they endangered
patient/doctor trust. Of doctors who prescribed impure placebos,
half (48%) told patients ‘this therapy has helped many other
patients,’ 18% told patients that the treatment promoted self-
healing, and 8% told the patient the treatment was a placebo.
Three respondents who used the free text option noted saline
injections were useful for treating opiate addicts inappropriately
presenting to emergency departments. Doctors who reported
finding impure placebos ‘never acceptable in clinical practice’ are
also less likely to prescribe them in clinical practice’ (91% versus
99%, RR 0.92, 95% CI 0.86 to 0.98). GPs who prescribed impure
placebos in spite of finding them ‘never acceptable’, did so for the
following common reasons: to calm the patient, because the
patient requested treatment, for possible psychological treatment
effect or as a supplement to medication. Sample sizes were too
small to formally analyze reasons for placebo use among doctors
who never found impure placebo use to be ethically acceptable.
Predictors of placebo use
There were differences between males and females in the
frequency of use of several placebos. More females used positive
suggestions on a frequent basis (64% versus 52%, RR 1.23, 95%
CI 1.08 to 1.40, P=0.0013), and more males prescribed off-label
uses of potentially effective therapy frequently (18% versus 10%
RR 1.82, 95% CI 1.23 to 2.71, P=0.0029). There was a
significant association between the number days per week spent in
practice and the frequency of use of non-essential physical exams.
92% of those working 0–3 days in practice used non-essential
physical exams frequently or occasionally compared to 77% of
those working 5 days or more (RR 1.19, 95% CI 1.07 to 1.32,
P=0.0014). We suspected females spent fewer days in practice and
this might have confounded the association between sex and
frequency of non-essential examinations. We repeated Fisher’s
exact test and found no significant associations between the
number of days per week spent in practice and frequency of non-
essential physical exam use for males or females (P=0.142).
Discussion
Summary of main findings
Placebos may represent one of the more commonly used
treatments in UK primary care in spite of (perhaps sometimes
unjustified) ethical constraints. Twelve percent of respondents
reported using pure placebos, and 97% reported using impure
placebos at least once in their career. Many placebos were used
frequently by over half the respondents, and most general
practitioners felt there were circumstances in which impure and
pure placebos were ethically acceptable. Half of the practitioners
who use placebos informed their patients that this intervention has
helped other patients without specifically telling them that they
were prescribing a placebo. This raises unresolved ethical issues
about how GPs approach informed consent in relation to their
prescriptions of placebos. The analysis indicates potential gender
differences in the frequency of placebo prescriptions.
Strengths and Limitations
Given ethical constraints surrounding placebo use in clinical
practice, general practitioners completing surveys may have
understated their use of placebos. The response rate (46%) raises
questions about representativeness, yet our respondents were
similar to GPs registered with the GMC.
Our pragmatic definition of ‘placebo’, while consistent with
other surveys, could be challenged. For example, it might turn out
that some conventional therapies that lack an evidence base
(considered to be placebos in our survey) are eventually proven to
be efficacious non-placebo treatments. In addition the distinction
between pure and impure placebos is only useful as a rough guide.
Just as antibiotic treatments can function as treatments (for
bacterial infections) or placebos (for viral infections), so sugar pills
and saline solutions can be treatments for some conditions and
placebos for others. For instance sugar is not inert with respect to
diabetes. [18,22,43] and saline solution is an effective treatment to
treat increased intracranial pressure. [44] The difference between
pure and impure placebos is therefore stochastic: pure placebos
are less often used as treatments as compared with impure
placebos.
We considered that for practical and internationally compar-
ative purposes it is more important to describe treatments often
labeled as placebos rather than resolve the philosophical debate
Table 3. Summary of practitioner beliefs about ethical acceptability of placebo use.
Percentage (95% CI) of GPs agreeing with statement for
Statement PURE placebos IMPURE Placebos
Placebos are acceptable when used for their psychological effect 52.8% (49.3 to 56.3) 58.3% (54.9 to 61.8)
Placebos are acceptable when all other therapies have been exhausted 49.7% (46.2 to 53.2) 66.5% (63.2 to 69.8)
Placebos are acceptable when the patient wants or expects this therapy 47.2% (43.7 to 50.7) 46.7% (43.2 to 50.2)
Placebos are acceptable when clinical experience has shown a benefit 60.7% (57.3 to 64.2) 79.0% (76.2 to 81.9)
Placebos are not acceptable when they involve deception 82.0% (79.3 to 84.7) 82.4% (79.7 to 85.0)
Placebos are not acceptable when they endanger patient/doctor trust 90.2% (88.1 to 92.2) 93.6% (91.9 to 95.3)
Placebos are not acceptable because the efficacy is insufficient 52.8% (49.3 to 56.3) 35.0% (31.7 to 38.4)
Placebos are not acceptable because of legal problems 61.4% (58.0 to 64.8) 45.3% (41.8 to 48.8)
Placebos are not acceptable because they have possible adverse effects 41.6% (38.1 to 45.0) 55.8% (52.3 to 59.2)
Placebos are acceptable in some circumstances in clinical practice 66.2% (62.9 to 69.6) 84.1% (81.6 to 86.7)
Placebos are never acceptable in clinical practice 32.5% (29.2 to 35.8) 13.9% (11.5 to 16.4)
doi:10.1371/journal.pone.0058247.t003
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over the definition of placebos. UK GPs appeared to agree with
our definition. 82% – 99% (depending on which placebo
treatment) agreed that the treatments listed as placebos were, in
fact, placebos.
Other limitations include potential recall and response bias.
[45,46] Given the ethical strictures against placebo use, these
biases may have let to an underestimate of reported placebo usage.
[47]
Costs and side-effects
A full cost analysis of placebo prescriptions is beyond the scope
of this work yet our data suggest placebos probably cost the NHS
many millions of pounds each year. [48,49] Besides the possible
financial burden, placebos can be harmful (in which case they are
referred to as ‘nocebos’ [50,51]). For example impure placebos
such as antibiotics can have serious adverse (‘nocebo’) effects. [52]
Other literature
The survey instrument was derived from previously published
investigations and enables our data to be easily compared with
other international studies. A 2009 systematic review of 22 surveys
of placebo use in general practice in 12 countries found 17% to
80% of practitioners had used ‘pure’ placebos at least once in their
career and between 54% and 57% had used impure placebos at
least once in their career. [5] The latest survey of placebo use was
published after the systematic review and found 45% of German
GPs had used pure placebos and 76% had used impure placebos
in the last year. [12] Hence the results of our UK survey are
internationally consistent.
Implications for future research and clinical practice
Placebos are commonly used in UK primary care. Clinical and
health service researchers have spent decades investigating ways to
effectively utilize ‘active’ conventional treatments safely, ethically
and intelligently. [53] The time has come to use similar methods to
investigate ways to rationalize placebo use. The long term viability
of placebo use in clinical practice depends on whether placebo
benefits outweigh harms, [54] their cost, and whether patients and
practitioners deem their use to be ethically acceptable. Further
investigations are warranted to develop ethical and cost-effective
placebos.
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